Episode Description
Welcome to Onco Life Centre Podcast.
In this episode, we break down the FDA's new accelerated approval for a breast cancer treatment guided by an early resistance blood test, and what it could mean for patients already in treatment.
You'll learn:
- Why the FDA called this the first cancer approval guided by a resistance mutation found in blood before a scan shows progression
- How a blood test for circulating tumor DNA works
- Why fewer than 5 percent of patients carry this resistance mutation at diagnosis, while nearly 40 percent develop it later
- What the pivotal trial found: 16 months without disease progression versus 9.2 months for patients who continued their original therapy
- Why an FDA advisory panel voted against calling the trial results clinically meaningful
- What conditions come with this accelerated approval, including a boxed warning for irregular heart rhythm
- Why this approach currently applies only to patients already diagnosed and already in treatment
This approval marks an early step toward monitoring breast cancer treatment resistance through blood rather than waiting for scans. Regulators still want more proof that earlier action extends survival, not just the time before the next scan.
Blog Link: Breast Cancer: Can a Blood Test Spot Resistance Earlier?
Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.
Author: Dr. CHRISTINA NG VAN TZE
📍 Visit us at oncolifecentre.com
📞 Call: +60 3 2242 3260
📧 Book a consultation or ask a question — we're here to support your journey.